Evaluation of the effect of Afsantin on COVID 19

Evaluation of the effect of Afsantin in the treatment of COVID 19 patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190415043279N6

Enrollment

Registered

2020-07-24

Start date

2020-07-10

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19. Other coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention 1: Intervention group: The Afsantin capsule is taken as a 1000 mg soft capsule four times a day for 14 days. Intervention 2: Control group: The placebo is taken as a capsule four times a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Definitive confirmation of Covid 19 based on RT-PCR results Hospitalized patients Ventilator independent patients

Exclusion criteria

Exclusion criteria: Pregnancy Breastfeeding Diabetes Severe renal failure Metabolic acidosis Severe respiratory failure Taking anticoagulants

Design outcomes

Primary

Measure	Time frame
Fever. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Thermometer.;Cough. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Questionnaire.;Muscle pain. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Questionnaire.;C Reactive Protein (CRP). Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Agglutination.;Blood oxygen saturation percentage. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Pulse oximeter.;CBC. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Cell Counter.;Respiratory Rate. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: By observing the occurrence of breaths.;Heart Rate. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Pulse oximeter.	—

Measure

Time frame

Fever. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Thermometer.;Cough. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Questionnaire.;Muscle pain. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Questionnaire.;C Reactive Protein (CRP). Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Agglutination.;Blood oxygen saturation percentage. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Pulse oximeter.;CBC. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Cell Counter.;Respiratory Rate. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: By observing the occurrence of breaths.;Heart Rate. Timepoint: At the beginning of the study (before the intervention) and after the intervention. Method of measurement: Pulse oximeter.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNoshad Mohammadi

Sanandaj University of Medical Sciences

noshad.50@gmail.com+98 87 3366 4645

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026